MONITORING HIV DRUG RESISTANCE WITH CADRE

Details

• Corporate Authors:
  Centers for Disease Control and Prevention (U.S.)
• Description:
  Use of antiretroviral therapy (ART) has increased significantly over the past decade. Nearly 80% of all people living with HIV worldwide received ART in 2022. In countries supported by the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR), over 90% of people living with HIV achieve viral suppression. Achieving viral suppression preserves the health of the person living with HIV and prevents transmission to sexual partners. The emergence of HIV drug resistance, however, can compromise the effectiveness of antiretroviral drugs and efforts to reduce the spread of HIV, prevent severe HIV disease, and prevent HIV-related deaths.
  
  It is a priority to monitor the emergence of and understand the risk factors for HIV drug resistance, especially resistance to dolutegravir (DTG)-based regimens, which account for 92% of ART dispensed with PEPFAR support.Surveillance of HIV drug resistance is critical for minimizing the emergence and spread of HIV drug resistance.
  
  Publication date from document properties.
  
  2024CADRE_Factsheet_MonitoringHIV.pdf
  
  
• Subjects:
  Anti-Retroviral Agents Antiretroviral Treatment Drug Resistance Drug Resistance, Viral HIV Infections
• Document Type:
  Pamphlet (or booklet)
• Genre:
  Fact Sheet
• Pages in Document:
  2 unnumbered pages
• Collection(s):
  Stephen B. Thacker CDC Library
• Main Document Checksum:
  urn:sha256:f6f9fd237c81366ced35912fa349b6861a4cadd325a588e27e751510591ba490
• Download URL:
  https://stacks.cdc.gov/view/cdc/156314/cdc_156314_DS1.pdf
• File Type:
  [PDF - 1.78 MB ]